Skip to content

Reversal of Atrial Substrate to Prevent Atrial

Atrial Fibrillation

A multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on recurrence of atrial fibrillation.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria: Patients with symptomatic (CCS-SAF ≥2) paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and at least two of the following:

* BMI ≥ 27,
* BP ≥140/90 mmHg or history of hypertension,
* Prior stroke/transient ischemic attack,
* Diabetes,
* Heart failure (prior heart failure admission or left ventricle ejection fraction (LVEF) \<40%),
* Age ≥ 65 years
* Current smoker
* Excessive Alcohol use

Exclusion Criteria:

* Permanent AF (AF lasting \> 3 years)
* Prior catheter ablation for AF
* New York Heart Association (NYHA) Class IV (Severe) heart failure,
* Participation in a cardiac rehabilitation program within the last year,
* Currently performing exercise training \>150 minutes/week of moderate to vigorous physical activity,
* Unable to exercise,
* Unable to give informed consent,
* Other noncardiovascular medical condition making 1 year survival unlikely,
* Less than 18 years of age.

Study Location

St. Paul's Hospital
St. Paul's Hospital
Vancouver, British Columbia
Canada

Contact Study Team

St. Mary's General Hospital
St. Mary's General Hospital
Kitchener, Ontario
Canada

Contact Study Team

Primary Contact

Umjeet Jolly

Backup Contact

Umjeet Jolly, MD, FRCPC

Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Eugene Crystal

Backup Contact

Eugene Crystal, MD, FRCPC

Sacre Coeur Hospital
Sacre Coeur Hospital
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Marcio Sturmer

Kelowna General Health
Kelowna General Health
Kelowna, British Columbia
Canada

Contact Study Team

Backup Contact

Chris Lane, MD, FRCPC

Primary Contact

Chris Lane

Hamilton Health Sciences Center
Hamilton Health Sciences Center
Hamilton, Ontario
Canada

Contact Study Team

Backup Contact

Jorge Wong, MD, FRCPC

Primary Contact

Jorge Wong

St. Michael's Hospital
St. Michael's Hospital
Toronto, Ontario
Canada

Contact Study Team

Backup Contact

Iqwal Mangat, MD, FRCPC

Primary Contact

Iqwal Mangat

Montreal Heart Institute
Montreal Heart Institute
Montreal, Quebec
Canada

Contact Study Team

Backup Contact

Lena Rivard, MD, FRCPC

Primary Contact

Lena Rivard

Foothills Hospital
Foothills Hospital
Calgary, Alberta
Canada

Contact Study Team

Backup Contact

Stephen Wilton, MD, FRCPC

Primary Contact

Stephen Wilton

Saint John Regional Hospital
Saint John Regional Hospital
Saint John, New Brunswick
Canada

Contact Study Team

Primary Contact

Satish Toal

Mazankowski Alberta Heart Institute
Mazankowski Alberta Heart Institute
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Ken Quadros

London Health Sciences Center
London Health Sciences Center
London, Ontario
Canada

Contact Study Team

Backup Contact

Allan Skanes, FRCPC

Primary Contact

Allan Skanes

QE II Health Sciences Centre
QE II Health Sciences Centre
Halifax, Nova Scotia
Canada

Contact Study Team

Primary Contact

Ratika Parkash

Backup Contact

Ratika Parkash, MD MSc

Ottawa Heart Institute
Ottawa Heart Institute
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

David Birnie

Backup Contact

David Birnie, MD, FRCPC

Laval Hospital
Laval Hospital
Laval, Quebec
Canada

Contact Study Team

Regina General Hospital
Regina General Hospital
Regina, Saskatchewan
Canada

Contact Study Team

Primary Contact

Omar Sultan

Backup Contact

Omar Sultan, MD, FRCPC

McGill University Health Centre
McGill University Health Centre
Montreal, Quebec
Canada

Contact Study Team

Study Sponsored By
Nova Scotia Health Authority
Participants Required
More Information
Study ID: NCT03682991